Female Urology

With this approval, flibanserin becomes the first and only treatment of its kind for women younger than 65 years.

Daré Bioscience said the sildenafil cream’s availability will expand to other states throughout December 2025 and early 2026.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

The agency is working with companies to update the language on HRT to remove references to risks of cardiovascular disease, breast cancer, and probable dementia.

A. Lenore Ackerman, MD, PhD, discusses how clinicians should approach conversations with patients on the risks and benefits of vaginal estrogen.

A. Lenore Ackerman, MD, PhD, outlines the rationale for a guideline recommendation suggesting that D-mannose alone may not be effective for UTI prophylaxis.

A. Lenore Ackerman, MD, PhD, outlines what the data suggest about non-antibiotic approaches for UTI prophylaxis, as well as how these options should be positioned when counseling patients.

A Lenore Ackerman, MD, discusses a recent guideline amendment that places a greater value on a negative urinalysis in ruling out UTI.

A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women.

The AUA has released updated guidelines for recurrent UTIs in women, emphasizing patient-centered care, nonantibiotic options, and improved clinical judgment.

We recap notable headlines from last month in the benign urology space.

“We hope our findings reassure health professionals caring for postmenopausal women with a history of stroke,” says Kimia Ghias Haddadan, MD.

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, emphasizes a careful, individualized approach to managing bladder and bowel symptoms in women with a history of disordered eating.

Aleece Fosnight, MSPAS, PA-C, emphasizes that any patient presenting with urinary incontinence or related symptoms should be evaluated for pelvic floor dysfunction.

On the urinary side, Fosnight prioritizes pelvic floor physical therapy as a first-line intervention for incontinence, citing evidence of significant symptom improvement.

"Major complications of ring pessaries are rare but present considerable challenges to surgeons and patients when they do occur," write E. Mackenzie Gibbs, MD, and Charles Lloyd Secrest, MD.

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

Ashley G. Winter, MD, reflects on the need for FDA approved testosterone formulations in women, emphasizing that urologists are well-positioned to drive change in this space.

“Right now, it is our counseling against the warning label,” Winter emphasized.

Findlay notes that urinary diversion has increased over time, potentially due to functional decline and growing burdens on patients and caregivers.

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

"We are not offering patients comprehensive management unless we consider hormone therapies," says Ashley G. Winter, MD.

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

Take a look back through some of the top stories from the first half of the year.